FDA’s Postmarket Drug Safety Pilot Will Consider Between Five And 10 Drugs
FDA expects to begin in March to develop the first safety profile under a pilot program for postmarket monitoring of new molecular entities
FDA expects to begin in March to develop the first safety profile under a pilot program for postmarket monitoring of new molecular entities